Prosecution Insights
Last updated: April 19, 2026
Application No. 17/950,735

Oral Care Compositions and Methods

Non-Final OA §103
Filed
Sep 22, 2022
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Colgate-Palmolive Company
OA Round
4 (Non-Final)
48%
Grant Probability
Moderate
4-5
OA Rounds
4y 4m
To Grant
85%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
363 granted / 750 resolved
-11.6% vs TC avg
Strong +36% interview lift
Without
With
+36.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
78 currently pending
Career history
828
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 750 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed November 11, 2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. This action is made Non-Final. Claims Claim Rejections - 35 USC § 103 – Obviousness (New Rejection) Claims 1-17 and 19-20 are rejected under 35 U.S.C. 103 as being unpatentable over in view of Midha et a. (2017/0281483). Midha et al. disclose an oral care composition containing a gel network phase, potassium nitrate, an abrasive and a fluoride ion source (Abstract). The oral composition include toothpaste (paragraph 0001). The oral care composition comprises (a) a gel network phase comprising from about 14% to about 20%, by weight of the composition, fatty amphiphile and a secondary surfactant; (b) from about 1% to about 8%, by weight of the composition, potassium nitrate (instant claim 1 (ii)); (c) from about 2% to about 25%, by weight of the composition, abrasive; (d) a fluoride ion source including stannous fluoride (instant claim 1(i)); wherein the fluoride ion source provides a fluoride ion concentration from about 0.005% to about 2.0%, by weight of the composition; wherein phase separation is not visually perceptible as determined by the phase separation method (paragraph 0008). The composition can contain another salt such as pyrophosphates for tartar control (paragraph 0020). The tartar control agents include the pyrophosphates salts and sodium tripolyphosphate include sodium salts. The pyrophosphate salt may comprise about 3% to about 8% by weight and include tetraalkali metal pyrophosphate salts, tetrasodium pyrophosphate, (paragraph 0082) (instant claim 1(iii)). Water comprises 15 to about 95% by weigh of the composition (paragraph 0071). An example comprises 20.26% water, 5% potassium nitrate, 0.11% sodium acid pyrophosphate and 0.24% sodium fluoride, which may be substituted with stannous fluoride (Ex. 1 and paragraph 0105). Antimicrobials may be added to the composition and include chlorhexidine and comprise 0.035% to about 2% by weight of the composition. The amounts disclosed by Midha et al. for the potassium nitrate, fluoride and polyphosphate salts encompass the ratios recited by instant claims 8 and 9. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. Chlorhexidine is a guanine. It would have been obvious to one of ordinary skill in the art to have added chlorhexidine to the composition of Midha et al. because Midha et al. suggests adding them to the disclosed compositions. Allowable Subject Matter Claim 18 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1-17 and 20 are rejected. No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached on 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Sep 22, 2022
Application Filed
Sep 07, 2024
Non-Final Rejection — §103
Dec 10, 2024
Response Filed
Mar 27, 2025
Final Rejection — §103
Jun 02, 2025
Response after Non-Final Action
Aug 04, 2025
Request for Continued Examination
Aug 06, 2025
Response after Non-Final Action
Aug 09, 2025
Non-Final Rejection — §103
Nov 11, 2025
Response Filed
Mar 08, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594229
Personal Care Compositions and Methods for the Same
2y 5m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
2y 5m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 5m to grant Granted Feb 24, 2026
Patent 12551417
STABILIZED STANNOUS COMPOSITIONS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

4-5
Expected OA Rounds
48%
Grant Probability
85%
With Interview (+36.4%)
4y 4m
Median Time to Grant
High
PTA Risk
Based on 750 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month